 |
Indication & Dosage |
| |
| |
| Intravenous |
| TREATMENT OF ACUTE HEART FAILURE AND MYOCARDIAL INFARCTION |
| Adult:
As hydrochloride: Initially, 1-5 mcg/kg/min increased gradually by up to 5-10 mcg/kg/min according to the patient's BP, cardiac output and urine output. Up to 20-50 mcg/kg/min may be required in seriously ill patients. |
|
| |
|
| Precautions |
Shock secondary to MI, history of peripheral vascular disease. Correct hypovolaemia before infusion. History of occlusive vascular disease e.g, atherosclerosis, Raynaud's disease, Buerger's disease, diabetic endarteritis; disproportionate increase in diastolic pressure. Pregnancy. |
| |
|
| Adverse Drug Reactions |
Nausea, vomiting, tachycardia, ectopic beats, palpitation, anginal pain, hypotension, vasoconstriction, bradycardia, hypertension, dyspnoea, headache, widened QRS complexes, azotaemia.
|
| |
|
| Interactions |
Cyclopropane and halogenated hydrocarbon anaesthetics may sensitise myocardium to dopamine and precipitate ventricular arrhythmias. MAO inhibitors prolong and increase dopamine effects. Ergots potentiate vasoconstriction action of dopamine. Alpha-blockers unmask dopamine's beta action. |
| |
|
|
|
